#1 Clinical Trials Search in Europe

VX-993

Clinical trials are investigating VX-993 in people with pain linked to diabetic peripheral neuropathy, a type of nerve pain caused by diabetes. The studies aim to evaluate whether VX-993 can reduce pain and how safe and tolerable it is. The current trial is in adults with this condition.

Table of Contents

Trial overview

The clinical trial for VX-993 is titled Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral Neuropathy.[1]

This is an interventional study, which means researchers give study treatment and then measure the results.[1]

The trial is in Phase 2 and is marked Authorised.[1]

The planned enrollment is 300 people.[1]

Who is being studied

This trial is studying people with pain associated with diabetic peripheral neuropathy.[1]

Diabetic peripheral neuropathy is nerve damage caused by diabetes, and it can lead to pain in the feet, hands, or other areas.[1]

The source data say the study is for subjects with this condition, but they do not give more detail about age limits or other eligibility rules.[1]

What the study measures

The main goal is to see whether VX-993 can improve pain in people with diabetic peripheral neuropathy.[1]

Researchers are also studying safety and tolerability, which means how well the treatment can be used and how well people can handle it.[1]

The primary outcome is the change from baseline in the weekly average of daily pain intensity on the numeric pain rating scale (NPRS) at Week 12.[1]

In simple terms, this means the study compares pain at the start with pain after 12 weeks to see if symptoms improve.[1]

Study design and treatment groups

The intervention list shows VX-993 tablet and placebo groups, and it also lists pregabalin and pregabalin placebo.[1]

A placebo is a look-alike treatment with no active study drug, used so researchers can compare results more fairly.[1]

The trial data do not provide more detail about the exact group assignment method, but they do show that VX-993 is being compared with placebo and with pregabalin-related study groups.[1]

What the results may mean

This trial is designed to answer a practical question: can VX-993 reduce pain in people living with diabetes-related nerve pain?[1]

Because it is a Phase 2 study, the results may help show whether the treatment is promising enough for later research.[1]

The study focuses on patient-reported pain scores, so the results depend on how participants rate their own pain over time.[1]

Trial ID Phase Condition studied Status Enrollment
NCT06619860 Phase 2 Pain associated with diabetic peripheral neuropathy Authorised 300

FAQ

  • What is being studied in VX-993 clinical trials? The trial is studying whether VX-993 can help reduce pain in people with diabetic peripheral neuropathy. It is also looking at safety and tolerability.
  • Who can take part in the VX-993 trial? The trial is for subjects with pain associated with diabetic peripheral neuropathy. The data provided do not list more detailed eligibility rules.
  • What phase is the VX-993 trial? The trial is a Phase 2 study. Phase 2 trials usually look more closely at whether a treatment works and continue safety checks.
  • What condition is VX-993 being tested for? VX-993 is being tested for pain associated with diabetic peripheral neuropathy. This is nerve pain related to diabetes.
  • What outcome is the trial measuring? The main outcome is the change in weekly average daily pain intensity on the numeric pain rating scale at Week 12. This means the study checks whether pain gets better over time.

Ongoing Clinical Trials on VX-993

  • Study on the Effectiveness and Safety of VX-993 and Pregabalin for Pain Relief in Patients with Diabetic Peripheral Neuropathy

    Recruiting

    2 1 1
    Investigated drugs:
    France Germany Italy

Glossary

  • Diabetic peripheral neuropathy: Nerve damage caused by diabetes that can lead to pain, numbness, or tingling, usually in the feet or hands.
  • Pain intensity: How strong pain feels to the person reporting it.
  • Numeric pain rating scale (NPRS): A pain scale where people rate their pain with numbers, often to show how severe the pain is.
  • Baseline: The starting point before treatment begins. Results are compared with this point.
  • Weekly average: The average result from several days in one week.
  • Daily pain intensity: How strong the pain feels each day.
  • Week 12: The 12th week of the study, when some results are checked.
  • Safety: How well a treatment can be used without causing harmful problems.
  • Tolerability: How well people can handle a treatment.
  • Phase 2: A mid-stage clinical trial that looks at whether a treatment may work and continues to study safety.
  • Interventional study: A study where researchers give a treatment and then measure the results.

References